A planned interim clinical trial analysis found Praxis Precision Medicines drug ulixacaltamide was unlikely to succeed as a treatment for essential tremor. But Praxis is continuing two late-stage tests of the drug; data are expected in the third quarter of 2025.
The post Praxis Presses Forward in Essential Tremor Despite Futility Finding From Trial Observers appeared first on MedCity News.
